Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBYOT.L Regulatory News (BYOT)

  • There is currently no data for BYOT

Directorate Change

11 May 2009 07:00

RNS Number : 9870R
Byotrol PLC
11 May 2009
 



Byotrol plc ("the Company")

Board Changes

The Board is pleased to announce the appointments of Ralph Kugler and Dr. Till Medinger as Non-executive Directors of the Company with immediate effect.

Mr Kugler, aged 53, is a Non-Executive Director of Intercontinental Hotels Group Plc and is chairman of the board's remuneration committee. He is Chairman of Gorkana Ltd, and a Senior Advisor to 3i PLC.

Mr Kugler was an executive director on the boards of Unilever PLC and Unilever NV from 2005-08. He was President of Unilever's global Home & Personal Care categories from 2005. Prior to that he had been President in Europe, Latin America, and previously Chairman and CEO of Unilever's businesses in Thailand and Malaysia.

Dr Medinger, aged 68, was formerly Senior Vice President for Corporate Strategy at AstraZeneca Plc and prior to that had a long and distinguished career with Zeneca Plc and ICI Pharmaceuticals, directing business and marketing operations internationally and overseeing the launch of several global blockbuster products. 

He is a past President of the Association of the British Pharmaceutical Industry and has many years international industry experience, serving on the Boards of both the European and the International Pharmaceutical Industry Federations. He has also served on the Board of the Chemical Industries Association. His business career has spanned R&D, territorial and marketing management, strategic planning, business operations, licensing and acquisitions/divestments, and public and government affairs. He has also acted as a corporate consultant to a number of emerging high-tech companies within the US and the UK

Dr Medinger is Chairman of PhotoBiotics Limited and non-executive director of Datapharm Communications Ltd and Polytherics Ltd. 

Wesley Devoto OBE has informed the Board that he will not seek re-election at the end of his term in June 2009, and will stand down as Non-Executive Chairman and as a director at the next Board meeting. Mr Devoto has led the Board through the initial stages of the company's development, the 2005 AIM flotation, and two subsequent fund raisings. The Board thanks Mr Devoto for his advice, counsel and leadership and wishes him well for the future.

Stephen Falder, Deputy Chairman and Business Development Director, will on an interim basis chair board meetings.

Following these board changes, the Company's Remuneration Committee will comprise Ralph KuglerChairman, Adrian Smith and Till Medinger. The Audit Committee will comprise Adrian SmithChairman, Till Medinger and Ralph Kugler.

Save as disclosed above, there are no further details required to be disclosed pursuant to schedule 2(g) of the AIM rules.

Commenting on the appointmentDavid McRobbie, Chief Executive, said:

"We would like to thank Wesley Devoto for his significant contributions to Byotrol's business development to date and we are delighted to welcome both Mr Kugler and DMedinger to the Company and are confident that their significant experience will make them key additions to the Board."

11 May 2009

Byotrol plc

Stephen Falder, 

Deputy Chairman Business Development Director

Richard Bell, 

Finance Director 

Tel 0161 277 9518

Charles Stanley Securities

(Nominated Adviser)

Philip Davies / Jen Boorer

Tel 020 7149 6000

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOAEAKSPEDPNEFE
Date   Source Headline
30th Apr 20247:00 amRNSCancellation - Byotrol Plc
29th Apr 20242:15 pmRNSSecondary Trading on Asset Match
23rd Apr 20246:00 pmRNSByotrol
22nd Apr 20244:44 pmRNSCapital Reorganisation Delay
22nd Apr 20241:27 pmRNSResults of General Meeting
15th Apr 202411:48 amRNSHolding(s) in Company
8th Apr 20247:00 amRNSHolding(s) in Company
2nd Apr 20243:27 pmRNSDirector Dealing
28th Mar 20247:00 amRNSProposed Cancellation
22nd Dec 202311:44 amRNSHolding(s) in Company
7th Dec 20237:00 amRNSHalf-year Report
14th Nov 20237:00 amRNSLaunch of PROCESSUS® Instrument Decontamination
14th Nov 20237:00 amRNSTrading Update
9th Nov 20233:43 pmRNSHolding(s) in Company
27th Sep 20237:00 amRNSBoard Changes
13th Sep 20233:33 pmRNSResult of AGM
8th Sep 20234:33 pmRNSDirector Dealing
7th Sep 20237:01 amRNSBoard Appointment
7th Sep 20237:00 amRNSTrading Update
29th Aug 20238:51 amRNSLaunch of CHEMGENE MEDLAB into human healthcare
23rd Aug 20237:00 amRNSInvestor Presentation via Investor Meet Company
31st Jul 20237:00 amRNSFinal Results
6th Jul 20237:00 amRNSPatent Grant for Novel Anti-viral Seaweed Extract
24th May 20233:14 pmRNSUS EPA approves Byotrol24 as long-lasting virucide
24th May 20238:51 amRNSDirector Dealing
28th Apr 20239:57 amRNSDirector Dealing
27th Apr 20237:00 amRNSTrading Update and Board Changes
1st Feb 20239:52 amRNSDirector Dealing
22nd Dec 20223:08 pmRNSDirector Dealing
19th Dec 202210:00 amRNSDirector Dealing
16th Dec 20227:00 amRNSGrant of Share Incentive Awards
12th Dec 20227:00 amRNSInterim results and Investor Presentation
22nd Nov 20227:00 amRNSDirectorate Changes
27th Sep 202211:15 amRNSPDMR Shareholding
22nd Sep 20225:21 pmRNSResult of AGM
8th Sep 20227:00 amRNSDirector Dealing
2nd Sep 202210:02 amRNSInvestor Presentation
30th Aug 20227:00 amRNSFinal Results
12th Aug 20223:30 pmRNSDirector Dealing
28th Jul 20227:00 amRNSCompletion of Convertible Loan Note Fundraising
11th Jul 20227:00 amRNSTrading Update and Notice of Results
22nd Apr 20229:14 amRNSHolding(s) in Company
2nd Mar 20227:00 amRNSTrading Update
12th Jan 20227:00 amRNSSenior Management Appointment
14th Dec 20219:06 amRNSSecond Price Monitoring Extn
14th Dec 20219:00 amRNSPrice Monitoring Extension
13th Dec 20217:00 amRNSDirectorate Change
9th Dec 20218:51 amRNSDirector Dealing
8th Dec 20217:00 amRNSInterim Results and Investor Presentation
2nd Nov 20217:00 amRNSDirectorate and Senior Management Changes

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.